

INVITATION

FRIDAY
MAY
17

SYMPOSIUM DURING 1st EBMT GVHD SUMMIT

EMERGING DATA ON THERAKOS ECP IN THE TREATMENT OF GVHD PATIENTS

RADISSON BLU SOBIESKI HOTEL, WARSAW, POLAND

This information is intended only for healthcare professionals in Europe, Middle East, Asia Pacific, LATAM and Australia.

PRELIMINARY AGENDA

Chair – Prof. Dr. med. Nicolaus Kröger, UKE Hamburg, Germany

12:40 – 13:00 **Lunch**

13:00 – 13:30 **Results from the 1st randomized trial using the new NIH criteria**

Prof. Madan Jagasia, M.B.B.S., M.S - Vanderbilt University Medical Center, Nashville, USA

13:30 – 14:00 **Clinical benefit of ECP induced Immunotolerance**

Prof. Dr. med. Hildegard Greinix, Medical University of Graz, Austria

All speakers are subject to contract.

This is a commercial programme run by Therakos (UK) Ltd, a Mallinckrodt Company

[Privacy policy](#) [Legal notice](#)

Learn more about Mallinckrodt Pharmaceuticals by visiting www.mallinckrodt.com

Mallinckrodt, the “M” brand mark and the Mallinckrodt Pharmaceuticals logo are trademarks of a Mallinckrodt company.

Other brands are trademarks of a Mallinckrodt company or their respective owners. © 2019 Mallinckrodt.

Item code: EU-1900025. Date of preparation: March 2019.

Although we have determined that we have a legitimate interest in using your data for marketing and sales purposes as per the terms of the current data protection legislation, you can opt-out by replying to this mail indicating “unsubscribe” in the email body. Our Privacy Notice provides additional information.